View Financial HealthBayer 配当と自社株買い配当金 基準チェック /06Bayer配当を支払う会社であり、現在の利回りは0.29%です。主要情報0.3%配当利回り0.04%バイバック利回り総株主利回り0.3%将来の配当利回り3.2%配当成長-12.4%次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向-3%最近の配当と自社株買いの更新Upcoming dividend of €0.11 per share Apr 20Upcoming dividend of €0.11 per share Apr 21Dividend of €0.11 announced Mar 10Upcoming dividend of €0.11 per share Apr 22Dividend of €0.11 announced Feb 22すべての更新を表示Recent updatesUpcoming dividend of €0.11 per share Apr 20Bayer AG Announces Appointment of Nelson Ambrogio as President of U.S. Pharmaceuticals, Effective May 1, 2026Apr 01Bayer Announces Kerendia Meets Primary Endpoint In Investigational Phase III Find-Ckd Study In Patients With Non-Diabetic Chronic Kidney DiseaseMar 16Bayer Aktiengesellschaft to Report Q4, 2026 Results on Feb 24, 2027Mar 12Bayer Aktiengesellschaft to Report Q3, 2026 Results on Nov 03, 2026Mar 09Full year 2025 earnings released: €3.69 loss per share (vs €2.60 loss in FY 2024) Mar 06Missouri Court Grants Preliminary Approval of Roundup Class Settlement to Resolve Current and Future ClaimsMar 06Bayer Aktiengesellschaft, Annual General Meeting, Apr 24, 2026Mar 05+ 2 more updatesBayer Reports Results for the Investigational Targeted Radionuclide Therapy 225Ac-PSMA-Trillium in Advanced Metastatic Prostate CancerFeb 28Bayer Announces XOFIGO (Radium-223 Dichloride) Plus Enzalutamide Demonstrates Significant Overall Survival Benefit In PEACE-3 Trial In Patients With Metastatic Castration-Resistant Prostate Cancer With Bone MetastasesFeb 26Monsanto Announces Roundup™ Class Settlement Agreement to Resolve Current and Future ClaimsFeb 18Bayer's Asundexian Demonstrated A Substantial 26% Reduction in Stroke After a Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack, With No Increase in ISTH Major Bleeding Versus PlaceboFeb 06Bayer to Present Results from Phase III Oceanic-Stroke Study of Asundexian in Secondary Stroke PreventionJan 27Askbio Inc. Announces Fda Acceptance of Investigational New Drug (Ind) Application for Ab-1009 Gene Therapy for Treatment of Late-Onset Pompe DiseaseJan 08Bayer Starts Phase IIa Study for Treatment of Patients with Alport SyndromeDec 04+ 1 more updateNew minor risk - Share price stability Dec 02Bayer Starts New Phase III Study with Mirena®? for the Treatment of Nonatypical Endometrial HyperplasiaDec 02+ 1 more updateBayer Announces Positive Topline Results from the Global Phase III Study Oceanic-Stroke, with Its Investigational, Once Daily, Oral FXIa Inhibitor asundexianNov 24U.S. FDA Approves HYRNUO®? (sevabertinib) for Previously Treated Patients with HER2-Mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerNov 21Bayer Aktiengesellschaft to Report Q2, 2026 Results on Aug 04, 2026Nov 14Third quarter 2025 earnings released: €0.98 loss per share (vs €4.26 loss in 3Q 2024) Nov 13Bayer AG Announces Chief Financial Officer ChangesNov 07+ 1 more updateBayer Announces New Phase III Investigational Data from the Pivotal Fine-One TrialNov 06Bayer Announces U.S. Food and Drug Administration Approval for Moderate to Severe Hot Flashes Due to MenopauseOct 25Hesperos and Bayer Consumer Health Develop First Human-On-A-Chip Model of Stress-Induced Cognitive DysfunctionOct 10Bayer First Company to Advance Cell Therapy as Well as Gene Therapy Against Parkinson's DiseaseSep 22Bayer®? Aspirin Introduces Aspirina to the U.S. Pain MarketAug 16Bayer Aktiengesellschaft to Report Q1, 2026 Results on May 12, 2026Aug 07+ 1 more updateSecond quarter 2025 earnings released: €0.20 loss per share (vs €0.035 loss in 2Q 2024) Aug 06Bayer Aktiengesellschaft to Report Q3, 2025 Results on Nov 12, 2025Jul 29Bayer Ag and BlueRock Therapeutics LP Announces First Patient Receives Investigational Therapy in Phase 1/2a Clinical Trial of OpCT-001 for the Treatment of Primary Photoreceptor DiseasesJul 08Bayer Announces Executive Changes for North AmericaJul 02Bayer Files for Approval of Gadoquatrane to the US Food and Drug AdministrationJun 19U.S. FDA Approves Third Indication of Darolutamide for Patients with Advanced Prostate CancerJun 05Vividion Therapeutics, Inc. and Bayer Further Strengthen Oncology Development Pipeline with Clinical-Stage WRN InhibitorJun 04+ 1 more updateElinzanetant Significantly Reduces Frequency of Moderate to Severe Vasomotor Symptoms Associated with Endocrine Therapy for Breast Cancer in Phase III Oasis-4 Study as Per BayerJun 03Bayer's XOFIGO (Radium-223 Dectloride) Combination Data Showcases Clinical Benefits in Metastatic Castration-Resistant Prostate Cancer with Bone MetastasesMay 29+ 1 more updateBayer Highlights New Data from Oncology and Women’S Health Portfolios At 2025 Asco Annual MeetingMay 21+ 1 more updateNew minor risk - Share price stability May 18First quarter 2025 earnings released: EPS: €1.32 (vs €2.04 in 1Q 2024) May 14Bayer Initiates Phase I Study Targeting GPC3 with Actinium-225 Radiopharmaceutical in Patients with Advanced Hepatocellular CarcinomaApr 30Bayer Announces Changes to CFO for Crop Science Division, Effective July 1, 2025Apr 29Upcoming dividend of €0.11 per share Apr 21Bayer to Unveil Latest NUBEQA®? (Darolutamide) Data and Prostate Cancer Research at American Urological Association (AUA) 2025 Annual MeetingApr 16Bayer Receives Full FDA Approval For VITRAKVI®? As First-In-Class TRK InhibitorApr 10Elliott Reportedly Gauge Investor Interest in Bayer's Consumer Health BusinessMar 28Bayer Announces Management Changes, Effective April 15, 2025Mar 25Bayer Announces U.S. FDA Accepts Supplemental New Drug Application Under Priority Review for New Indication for KERENDIA®? (Finerenone) in Patients with Heart Failure with Left Ventricular Ejection Fraction of 40%Mar 17Dividend of €0.11 announced Mar 10Full year 2024 earnings released: €2.60 loss per share (vs €2.99 loss in FY 2023) Mar 06Bayer Introduces Vyconic Soybeans at Commodity Classic 2025Mar 05Bayer Submits Supplemental New Drug Application to U.S. FDA Seeking New Indication for KERENDIA® (finerenone)Jan 10+ 1 more updateBayer Announces Positive Topline Results of Phase Iii Study Oasis 4 Investigating ElinzanetantJan 09Bayer Submits Application in China for Third Indication of DarolutamideJan 07Bayer Aktiengesellschaft to Report Q2, 2025 Results on Aug 06, 2025Dec 11Bayer to Present New Prespecified Subgroup Analyses from Investigational Phase III FINEARTS-HF Trial in Patients with Heart Failure with LVEF =40% at AHA 2024Nov 15Third quarter 2024 earnings released: €4.26 loss per share (vs €4.65 loss in 3Q 2023) Nov 13Bayer and Liveo Research Launches Blister Packaging with Improved Environmental FootprintOct 30Bayer Submits Application for Third Indication of Darolutamide in the EUOct 14U.S. Food and Drug Administration Accepts New Drug Application for Bayer's ElinzanetantOct 09Bayer Ag and BlueRock Therapeutics LP Announces Positive 24-Month Data from exPDiteSep 29Bayer Submits Application to U.S. FDA for Third Indication of darolutamideSep 26Bayer to Unveil New Data from its Phase III OASIS 3 Long-Term Study of Elinzanetant in the Treatment of Vasomotor Symptoms Associated with MenopauseSep 04Bayer Announces Late-Breaking KERENDIA® (finerenone) Investigational Data PresentedSep 02Bayer to Present Phase III Kerendia (Finerenone) DataAug 30Second quarter 2024 earnings released: €0.03 loss per share (vs €1.92 loss in 2Q 2023) Aug 07Bayer Announces Primary Endpoint Achieved in Phase III FINEARTS-HF Cardiovascular Outcomes Study Investigating KERENDIA in Patients with Heart Failure with Mildly Reduced or Preserved Ejection FractionAug 05Bayer Submits New Drug Application to U.S. FDA for Elinzanetant for the Treatment of Moderate to Severe Vasomotor Symptoms Associated With MenopauseAug 02Bayer Presents Latest Data from Oncology Portfolio at 2024 ASCO Annual MeetingMay 18Bayer Starts Phase I Study with Novel Targeted Radionuclide Therapy 225Ac-Psma-Trillium in Advanced Metastatic Prostate CancerMay 16First quarter 2024 earnings released: EPS: €2.04 (vs €2.22 in 1Q 2023) May 15Bayer to Unveil Late-Breaking Data from Phase Iii Oasis 1 and 2 for Elinzanetant in the Treatment of Vasomotor Symptoms Associated with MenopauseMay 09Upcoming dividend of €0.11 per share Apr 22Bayer AG and Asklepios BioPharmaceutical, Inc Presents Results from the 18-Month Phase Ib Clinical Trial for AB-1005Apr 16Bayer Appoints Sue Ann Pentecost as Head of U.S. Pharmaceutical CommunicationsApr 02Bayer Announces Positive Topline Results from Phase III Long-Term Study Oasis 3 Support Submits for Marketing Authorization for Bayer's ElinzanetantMar 20Bayer Aktiengesellschaft, Annual General Meeting, Apr 25, 2025Mar 12+ 3 more updatesFull year 2023 earnings released: €2.99 loss per share (vs €4.22 profit in FY 2022) Mar 05Dividend of €0.11 announced Feb 22Bayer Announces Start of Phase II Clinical Trial with BAY3018250Feb 20Bayer Aktiengesellschaft to Report Q1, 2024 Results on May 14, 2024Feb 07+ 1 more updateBayer Aktiengesellschaft to Report Q4, 2023 Results on Mar 05, 2024Jan 23+ 1 more update決済の安定と成長配当データの取得安定した配当: 1BAYNはItalian市場で注目すべき配当金を支払っていないため、支払いが安定しているかどうかを確認する必要はありません。増加する配当: 1BAYNはItalian市場で注目すべき配当金を支払っていないため、支払額が増加しているかどうかを確認する必要はありません。配当利回り対市場Bayer 配当利回り対市場1BAYN 配当利回りは市場と比べてどうか?セグメント配当利回り会社 (1BAYN)0.3%市場下位25% (IT)1.7%市場トップ25% (IT)4.6%業界平均 (Pharmaceuticals)2.8%アナリスト予想 (1BAYN) (最長3年)3.2%注目すべき配当: 1BAYNの配当金 ( 0.29% ) はItalian市場の配当金支払者の下位 25% ( 1.65% ) と比べると目立ったものではありません。高配当: 1BAYNの配当金 ( 0.29% ) はItalian市場の配当金支払者の上位 25% ( 4.57% ) と比較すると低いです。株主への利益配当収益カバレッジ: 1BAYN Italian市場において目立った配当金を支払っていません。株主配当金キャッシュフローカバレッジ: 1BAYN Italian市場において目立った配当金を支払っていません。高配当企業の発掘7D1Y7D1Y7D1YIT 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日(UTC時間)企業分析2026/05/04 07:41終値2026/05/04 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM(Trailing Twelve Month)またはLTM(Last Twelve Month)データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Bayer Aktiengesellschaft 18 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。41 アナリスト機関Rafael Bonardell TrianesBanco de Sabadell. S.A.Mark PurcellBarclaysCharles PitmanBarclays38 その他のアナリストを表示
Bayer AG Announces Appointment of Nelson Ambrogio as President of U.S. Pharmaceuticals, Effective May 1, 2026Apr 01
Bayer Announces Kerendia Meets Primary Endpoint In Investigational Phase III Find-Ckd Study In Patients With Non-Diabetic Chronic Kidney DiseaseMar 16
Missouri Court Grants Preliminary Approval of Roundup Class Settlement to Resolve Current and Future ClaimsMar 06
Bayer Reports Results for the Investigational Targeted Radionuclide Therapy 225Ac-PSMA-Trillium in Advanced Metastatic Prostate CancerFeb 28
Bayer Announces XOFIGO (Radium-223 Dichloride) Plus Enzalutamide Demonstrates Significant Overall Survival Benefit In PEACE-3 Trial In Patients With Metastatic Castration-Resistant Prostate Cancer With Bone MetastasesFeb 26
Bayer's Asundexian Demonstrated A Substantial 26% Reduction in Stroke After a Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack, With No Increase in ISTH Major Bleeding Versus PlaceboFeb 06
Bayer to Present Results from Phase III Oceanic-Stroke Study of Asundexian in Secondary Stroke PreventionJan 27
Askbio Inc. Announces Fda Acceptance of Investigational New Drug (Ind) Application for Ab-1009 Gene Therapy for Treatment of Late-Onset Pompe DiseaseJan 08
Bayer Starts New Phase III Study with Mirena®? for the Treatment of Nonatypical Endometrial HyperplasiaDec 02+ 1 more update
Bayer Announces Positive Topline Results from the Global Phase III Study Oceanic-Stroke, with Its Investigational, Once Daily, Oral FXIa Inhibitor asundexianNov 24
U.S. FDA Approves HYRNUO®? (sevabertinib) for Previously Treated Patients with HER2-Mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerNov 21
Bayer Announces U.S. Food and Drug Administration Approval for Moderate to Severe Hot Flashes Due to MenopauseOct 25
Hesperos and Bayer Consumer Health Develop First Human-On-A-Chip Model of Stress-Induced Cognitive DysfunctionOct 10
Bayer First Company to Advance Cell Therapy as Well as Gene Therapy Against Parkinson's DiseaseSep 22
Bayer Ag and BlueRock Therapeutics LP Announces First Patient Receives Investigational Therapy in Phase 1/2a Clinical Trial of OpCT-001 for the Treatment of Primary Photoreceptor DiseasesJul 08
Vividion Therapeutics, Inc. and Bayer Further Strengthen Oncology Development Pipeline with Clinical-Stage WRN InhibitorJun 04+ 1 more update
Elinzanetant Significantly Reduces Frequency of Moderate to Severe Vasomotor Symptoms Associated with Endocrine Therapy for Breast Cancer in Phase III Oasis-4 Study as Per BayerJun 03
Bayer's XOFIGO (Radium-223 Dectloride) Combination Data Showcases Clinical Benefits in Metastatic Castration-Resistant Prostate Cancer with Bone MetastasesMay 29+ 1 more update
Bayer Highlights New Data from Oncology and Women’S Health Portfolios At 2025 Asco Annual MeetingMay 21+ 1 more update
Bayer Initiates Phase I Study Targeting GPC3 with Actinium-225 Radiopharmaceutical in Patients with Advanced Hepatocellular CarcinomaApr 30
Bayer to Unveil Latest NUBEQA®? (Darolutamide) Data and Prostate Cancer Research at American Urological Association (AUA) 2025 Annual MeetingApr 16
Bayer Announces U.S. FDA Accepts Supplemental New Drug Application Under Priority Review for New Indication for KERENDIA®? (Finerenone) in Patients with Heart Failure with Left Ventricular Ejection Fraction of 40%Mar 17
Bayer Submits Supplemental New Drug Application to U.S. FDA Seeking New Indication for KERENDIA® (finerenone)Jan 10+ 1 more update
Bayer to Present New Prespecified Subgroup Analyses from Investigational Phase III FINEARTS-HF Trial in Patients with Heart Failure with LVEF =40% at AHA 2024Nov 15
Bayer to Unveil New Data from its Phase III OASIS 3 Long-Term Study of Elinzanetant in the Treatment of Vasomotor Symptoms Associated with MenopauseSep 04
Bayer Announces Primary Endpoint Achieved in Phase III FINEARTS-HF Cardiovascular Outcomes Study Investigating KERENDIA in Patients with Heart Failure with Mildly Reduced or Preserved Ejection FractionAug 05
Bayer Submits New Drug Application to U.S. FDA for Elinzanetant for the Treatment of Moderate to Severe Vasomotor Symptoms Associated With MenopauseAug 02
Bayer Starts Phase I Study with Novel Targeted Radionuclide Therapy 225Ac-Psma-Trillium in Advanced Metastatic Prostate CancerMay 16
Bayer to Unveil Late-Breaking Data from Phase Iii Oasis 1 and 2 for Elinzanetant in the Treatment of Vasomotor Symptoms Associated with MenopauseMay 09
Bayer AG and Asklepios BioPharmaceutical, Inc Presents Results from the 18-Month Phase Ib Clinical Trial for AB-1005Apr 16
Bayer Announces Positive Topline Results from Phase III Long-Term Study Oasis 3 Support Submits for Marketing Authorization for Bayer's ElinzanetantMar 20